EREG and breast cancer: In addition, LINC00885 is associated with early stage BC through the activation of epidermal growth factor receptor (EGFR), epiregulin (EREG), and forkhead box M1 (FOXM1) pathways and signaling pathways linked to TP53 signaling [66].